← All trials
NCT06094777
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2023
- Primary completion
- Jun 30, 2025
- Completion date
- Dec 31, 2025
- First posted
- Oct 23, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai YingLi Pharmaceutical Co. Ltd.Lead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.